In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
For those patients who have failed anti-TNF alpha therapy, what is the next best step? Is Entyvio, Stelara, or Xeljanz more effective?
Many patients, myself included, have either not responded to anti-TNF therapies or have lost response. It would be helpful for both doctors and patients to know what the next best step is.
IBD can have a significant impact on motility and gut absorption. Most medication pharmacokinetic studies are completed using healthy volunteers. If there is a significant impact on oral medication absorption/pharmacokinetics with active IBD, this may have an important role in determining a safe and effective dose.
I take it now on the advice of my functional medicine doctor, and think it helps me...
As this is a drug being regularly used and although not relatively new, the known long term side effects are not widely known
Multiple doctors have recommended that I start treatment for my Crohn's disease. There are many options from diet change, steroids, and immonosuapresants. My CD is very active and I have already had two surgeries.
Suffered two Incidence of Squamis Cell Carcinoma of the Lower Lip since being on 6mp
After treatment failure with an anti-TNFa biologic medication (eg. Remicade, Humira), should patients attempt alternative anti-TNFa biologics or with biologic medications with different mechanisms?
Many patients experience diminished efficacy or complete loss of efficacy with anti-TNFa biologics. Which subsequent biologic medication option is most effective and safe?
Is there a correlation between the use of NSAIDS (Ibuprofen) or other medications known to cause a "leaky gut" and the onset/development of IBD?
I took a large amount of Ibuprofen throughout my teen years for migraines. I have been told that taking Ibuprofen now can cause me to come out of remission due to causing a leaky gut and so I am curious to see if these types of medications can cause or trigger the onset of IBD in adolescents or in patient who chronically take these forms of medications.
I would like more research done on using the combination of a biologic (Humira) and Azathioprine (Imuran) together for treatment of crohns. Are the benefits really worth the risk? or is the risk not that bad?
I am on both of these meds and I have been questioned by my pharmacist about taking both of them together. I have read about the risks, and I'm not sure if I really do need both of the drugs. The information I have read seems to imply that getting cancer at some point is almost a certainty.
Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome (IBD-IBS) on patient reported outcomes in CCFA Partners
Variation in Care of Inflammatory Bowel Diseases Patients in CCFA Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures